Loading
A phase 1/2 trial of Pembrolizumab in merkel cell carcinoma and non-Hodgkin lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21) is a phase 1/2 interventional study registered as NCT07302347 by Merck Sharp & Dohme LLC, with 20 participants planned, started 2026-06-23 and due to reach its primary completion in 2029-03-30. Interventions recorded: Pembrolizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/